You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib
|
|---|---|
| Published in |
Annals of Hematology, March 2017
|
| DOI | 10.1007/s00277-017-2973-2 |
| Pubmed ID | |
| Authors |
Varinder Kaur, Arjun Swami |
| Abstract |
Bruton's tyrosine kinase (BTK), a mediator in B cell receptor signaling has been successfully exploited as a therapeutic target in treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Ibrutinib is a BTK inhibitor that has shown excellent efficacy in treatment-naïve, heavily pre-treated, and high-risk CLL/SLL. With remarkable efficacy, good oral bioavailability, and modest adverse events profile, ibrutinib use is likely to continue to increase. As data with ibrutinib use in CLL matures, concerns regarding adverse events and drug resistance have emerged. New insights into mechanisms of ibrutinib resistance in CLL have uncovered potential therapeutic targets. Several promising novel agents are currently in early phases of development for overcoming ibrutinib resistance in CLL/SLL. We provide a comprehensive analysis of emerging adverse events profile of ibrutinib, summarize our current understanding of ibrutinib resistance in CLL, and review promising novel therapeutic tools to overcome this challenge. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 20% |
| Spain | 1 | 20% |
| Canada | 1 | 20% |
| Unknown | 2 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 114 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| Unknown | 113 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 18 | 16% |
| Researcher | 18 | 16% |
| Student > Master | 14 | 12% |
| Student > Bachelor | 14 | 12% |
| Unspecified | 7 | 6% |
| Other | 25 | 22% |
| Unknown | 18 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 31 | 27% |
| Biochemistry, Genetics and Molecular Biology | 13 | 11% |
| Chemistry | 13 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 7% |
| Unspecified | 7 | 6% |
| Other | 23 | 20% |
| Unknown | 19 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 January 2024.
All research outputs
#6,716,476
of 25,323,244 outputs
Outputs from Annals of Hematology
#374
of 2,387 outputs
Outputs of similar age
#98,839
of 315,441 outputs
Outputs of similar age from Annals of Hematology
#4
of 20 outputs
Altmetric has tracked 25,323,244 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 2,387 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,441 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.